GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GlycoMimetics Inc (FRA:GKO) » Definitions » Cyclically Adjusted PB Ratio

GlycoMimetics (FRA:GKO) Cyclically Adjusted PB Ratio : 0.09 (As of May. 16, 2024)


View and export this data going back to 2014. Start your Free Trial

What is GlycoMimetics Cyclically Adjusted PB Ratio?

As of today (2024-05-16), GlycoMimetics's current share price is €0.252. GlycoMimetics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €2.96. GlycoMimetics's Cyclically Adjusted PB Ratio for today is 0.09.

The historical rank and industry rank for GlycoMimetics's Cyclically Adjusted PB Ratio or its related term are showing as below:

FRA:GKO' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.07   Med: 0.4   Max: 0.98
Current: 0.09

During the past years, GlycoMimetics's highest Cyclically Adjusted PB Ratio was 0.98. The lowest was 0.07. And the median was 0.40.

FRA:GKO's Cyclically Adjusted PB Ratio is ranked better than
89.94% of 646 companies
in the Biotechnology industry
Industry Median: 1.76 vs FRA:GKO: 0.09

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

GlycoMimetics's adjusted book value per share data for the three months ended in Mar. 2024 was €0.413. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €2.96 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


GlycoMimetics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for GlycoMimetics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlycoMimetics Cyclically Adjusted PB Ratio Chart

GlycoMimetics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 0.36 0.85 0.74

GlycoMimetics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.35 0.52 0.46 0.74 0.97

Competitive Comparison of GlycoMimetics's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, GlycoMimetics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GlycoMimetics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GlycoMimetics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where GlycoMimetics's Cyclically Adjusted PB Ratio falls into.



GlycoMimetics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

GlycoMimetics's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=0.252/2.96
=0.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GlycoMimetics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, GlycoMimetics's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.413/131.7762*131.7762
=0.413

Current CPI (Mar. 2024) = 131.7762.

GlycoMimetics Quarterly Data

Book Value per Share CPI Adj_Book
201406 2.489 100.560 3.262
201409 2.370 100.428 3.110
201412 2.175 99.070 2.893
201503 2.156 99.621 2.852
201506 2.587 100.684 3.386
201509 2.280 100.392 2.993
201512 1.950 99.792 2.575
201603 1.619 100.470 2.123
201606 1.889 101.688 2.448
201609 1.613 101.861 2.087
201612 1.439 101.863 1.862
201703 1.250 102.862 1.601
201706 3.140 103.349 4.004
201709 2.782 104.136 3.520
201712 2.944 104.011 3.730
201803 4.543 105.290 5.686
201806 4.533 106.317 5.619
201809 4.333 106.507 5.361
201812 4.184 105.998 5.202
201903 3.951 107.251 4.855
201906 3.659 108.070 4.462
201909 3.499 108.329 4.256
201912 3.193 108.420 3.881
202003 3.083 108.902 3.731
202006 2.771 108.767 3.357
202009 2.454 109.815 2.945
202012 2.150 109.897 2.578
202103 2.039 111.754 2.404
202106 1.808 114.631 2.078
202109 1.586 115.734 1.806
202112 1.381 117.630 1.547
202203 1.179 121.301 1.281
202206 1.006 125.017 1.060
202209 0.927 125.227 0.975
202212 0.745 125.222 0.784
202303 0.904 127.348 0.935
202306 0.786 128.729 0.805
202309 0.678 129.860 0.688
202312 0.547 129.419 0.557
202403 0.413 131.776 0.413

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


GlycoMimetics  (FRA:GKO) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


GlycoMimetics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of GlycoMimetics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


GlycoMimetics (FRA:GKO) Business Description

Industry
Traded in Other Exchanges
Address
9708 Medical Center Drive, Rockville, MD, USA, 20850
GlycoMimetics Inc is a clinical stage biotechnology company. It is focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the company is developing a pipeline of proprietary glycomimetics that may inhibit disease-related functions of carbohydrates, such as the roles it plays in inflammation, cancer, and infection.